ACT FOR ULTRA RARE

Lobbying client · District of Columbia · filed 2026 to 2026

Advocacy for ultra rare disease

$112,500 Reported spend

4 Filings counted

1 Outside firm hired

0 Bills named

Spend is reported income plus in-house expenses across 4 filings. Everything on this page comes from one LDA client record (72610), filed by the registrant listed below.

Who filed for this client 1

AVIVA STRATEGIES (FKA MGB CONSULTING) $112,500 Outside firm · 4 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Reported by year 1 year

2026 $112,500 4 filings

Issues lobbied 1

Health Issues 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 1

HOUSE OF REPRESENTATIVES 3

Recent filings 4 total

Q3 report

AVIVA STRATEGIES (FKA MGB CONSULTING)

3rd Quarter 2026 (July 1 - Sep 30) · House · $37,500 income · posted Oct 19, 2026

View → Q2 report

AVIVA STRATEGIES (FKA MGB CONSULTING)

2nd Quarter 2026 (Apr 1 - June 30) · House · $37,500 income · posted Jul 17, 2026

View → Q1 report

AVIVA STRATEGIES (FKA MGB CONSULTING)

1st Quarter 2026 (Jan 1 - Mar 31) · House · $37,500 income · posted Apr 20, 2026

View → Registration

AVIVA STRATEGIES (FKA MGB CONSULTING)

1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 17, 2026

View →

Affiliated organisations 2

CHIESI USA United States of America named on 1 filing
ULTRAGENYX United States of America named on 1 filing

Section 6 of the LD-2: organisations that contribute to or take part in this client's lobbying.

Keep going

Filings through October 19, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.